Navigation Links
$9.55 million NCI grant targets the resistance of advanced prostate cancer

When caught in its early stages, prostate cancer is treatable in most cases. But once it reaches a critical threshold, the disease becomes largely resistant to current treatments. The National Cancer Institute (NCI) recently awarded a team of cancer biologists $9.55 million over five years to define the molecular changes that occur as prostate cancer progresses to the therapy-resistant state.

The Program Project Grant (P01), "Signaling and Progression in Prostate Cancer," brings together a multi-disciplinary team of basic scientists and physician scientists at the University of Colorado Cancer Center and the University of Virginia.

"We are excited for the opportunity to bring together some of the world's top researchers in prostate cancer to explore the changes that turn a largely treatable disease into one with a 28 percent five-year survival rate," says Dan Theodorescu, MD, PhD, director of the University of Colorado's Cancer Center and Paul Bunn professor of Surgery and Pharmacology at the CU School of Medicine, co-principal investigator on this study.

"These changes include alterations in how the cancer cells respond to signals and what genes are expressed," says Bryce M. Paschal, PhD, professor of biochemistry and molecular genetics and member of the Center for Cell Signaling at the University of Virginia School of Medicine. "Understanding these changes are expected to reveal new drug targets and provide a knowledge base for improving prostate cancer therapies."

Specifically, Theodorescu and Paschal and collaborators will explore how cell growth, adaptation to limited nutrients, and cell motility contribute to the disease's progression to its therapy-resistant form.

"We're essentially trying to determine which pathways are altered with disease progression," Paschal says.

To discover these altered pathways, the Program Project Grant will utilize a number of cutting-edge technologies, including molecular imaging, ultra-high throughput DNA sequencing, and the development of new transgenic animal models designed to mimic the changes that occur in human prostate cancer.

"The biology of prostate cancer is heterogenous and so we hope to combat it with a team whose specialties are equally so," Theodorescu says.

The three projects in the P01 program include determining how hypoxic signals alter gene expression (Theodorescu), creating new transgenic mouse models to determine how kinases cooperate to drive tumorigenesis (Paschal), and examining how micro RNAs regulate cell proliferation and prostate cancer progression (Dutta).

Members at the University of Colorado Cancer Center also include Scott Lucia, MD, professor of pathology, and Jeffry Kieft, PhD, associate professor of biochemistry and molecular genetics.

University of Virginia team members also include Anindya Dutta, MD, PhD, professor and chair of the Department of Biochemistry and Molecular Genetics; Henry Frierson, MD, professor of pathology; Mark Conway, PhD, professor of biostatistics; David Wotton, PhD, associate professor of biochemistry and molecular genetics; and Dan Gioeli, PhD, assistant professor of microbiology, immunology, and cancer biology.


Contact: Garth Sundem
University of Colorado Denver

Related medicine news :

1. Amway One by One Campaign for Children Reaches 7 Million Kids
2. Michael J. Fox Foundation Awards $1 Million to Drive Critical New Research Tools and Technologies in Parkinsons Drug Development
3. International Diabetes Federation awards $2 million to 9 global diabetes research projects
4. New Report: $1 Cigarette Tax Increase Would Raise $418.8 Million for Texas and Cut Youth Smoking
5. New Report: $1 Cigarette Tax Increase Would Raise $18.6 Million for Montana and Cut Youth Smoking
6. New Report: $1 Cigarette Tax Increase Would Raise $24.8 Million for Wyoming and Cut Youth Smoking
7. New Report: $1 Cigarette Tax Increase Would Raise $43.3 Million for Utah and Cut Youth Smoking
8. New Report: $1 Cigarette Tax Increase Would Raise $113.9 Million for Colorado and Cut Youth Smoking
9. New Report: $1 Cigarette Tax Increase Would Raise $65.3 Million for Iowa and Cut Youth Smoking
10. Kaiser Permanente Approves $170 Million in Community Benefit Grants in 2009
11. America's Hidden Pandemic: 100 Million Suffer From Sleep Problems
Post Your Comments:
(Date:10/13/2017)... ... ... While it’s often important to take certain medications during the night, finding ... identified a solution. , She developed a prototype for MOTION LIGHT-UP PILL BOX to ... the need to turn on a light when taking medication during the night, allowing ...
(Date:10/13/2017)... Ill. (PRWEB) , ... October ... ... Edwardsville School of Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer ... healthcare professionals on guideline updates for the primary prevention of cardiovascular diseases ...
(Date:10/13/2017)... RIDGE, N.J. (PRWEB) , ... October 13, 2017 , ... ... annual Holly Day Market. Featuring a collection of specialty vendors and unique items from ... of personalized and quality-focused health and wellness services offered by the VNA. The ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 12, 2017 AVACEN Medical , Inc. (AVACEN) ... their  2017 New Product Innovation Award for Its fibromyalgia ... and secondary medical device market research by Frost & Sullivan,s ... OTC, drug-free pain relief product, the AVACEN 100, offers a ... fibromyalgia widespread pain. ...
(Date:10/11/2017)... Oct. 11, 2017  Caris Life Sciences ® , ... the promise of precision medicine, today announced that St. ... Precision Oncology Alliance™ (POA) as its 17 th ... St. Jude Crosson Cancer Institute will help develop standards ... of tumor profiling, making cancer treatment more precise and ...
(Date:10/10/2017)... , Oct. 10, 2017   West Pharmaceutical ... innovative solutions for injectable drug administration, today shared the ... ID Adapter for improving the intradermal administration of polio ... Skin Vaccination Summit in May 2017 by Dr. ... Polio Department, World Health Organization (WHO), and recently published ...
Breaking Medicine Technology: